Glycated Albumin Assay Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Diabetes

Glycated Albumin Assay Market

The global Glycated Albumin Assay Market is estimated to be valued at US$ 571.0 million in 2023 and is expected to exhibit a CAGR of 8.07% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Glycated Albumin assay is a diagnostic test used to measure the levels of glycated albumin in the blood. Glycated albumin is formed when glucose molecules bind to serum albumin protein. The assay is primarily used for the diagnosis and management of diabetes. The advantages of the glycated albumin assay include its ability to provide a shorter-term indicator of glycemic control compared to other tests such as HbA1c, its sensitivity to changes in blood glucose levels, and its reliability in patients with certain conditions that can affect HbA1c levels.

Market Key Trends:

One key trend in the Glycated Albumin Assay Market is the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation (IDF), in 2019, approximately 463 million adults (20-79 years) were living with diabetes, and this number is expected to rise to 700 million by 2045. This increasing prevalence of diabetes is driving the demand for glycated albumin assays as they provide a valuable tool in the diagnosis and management of the disease. Additionally, the glycated albumin assay offers advantages over other tests, such as HbA1c, making it an attractive option for healthcare professionals.

In conclusion, the Glycated Albumin Assay Market is projected to witness high growth due to the increasing prevalence of diabetes and the advantages offered by the glycated albumin assay in the diagnosis and management of the disease.

PEST Analysis:

Political: The political environment can directly impact the Glycated Albumin Assay market. Government regulations and policies related to healthcare and diagnostic tests can affect the market's growth prospects. Changes in healthcare reimbursement policies and regulations regarding diagnostic tests may influence the adoption of Glycated Albumin Assays.

Economic: The economic factors play a crucial role in shaping the market. Economic growth, healthcare expenditure, and per capita income affect the demand for diagnostic tests. The Glycated Albumin Assay market is expected to witness high growth due to increasing healthcare spending and rising prevalence of diabetes worldwide.

Social: Social factors such as changing lifestyles, increasing awareness about preventive healthcare, and the aging population have a significant impact on the market. The growing prevalence of diabetes and the need for early diagnosis are driving the demand for Glycated Albumin Assays.

Technological: Technological advancements in diagnostic tests and laboratory equipment have a strong impact on the market. The development of innovative and accurate assays enhances the efficiency and accuracy of diabetes diagnosis. The Glycated Albumin Assay market is witnessing advancements in technology, such as automated systems and point-of-care testing, which are driving market growth.

Key Takeaways:

The global Glycated Albumin Assay market is expected to witness high growth, exhibiting a CAGR of 8.07% over the forecast period. This growth can be attributed to the increasing prevalence of diabetes worldwide and the need for accurate and early diagnosis. The rising healthcare expenditure and growing awareness about preventive healthcare are also contributing to market growth.

In terms of regional analysis, North America is expected to be the fastest-growing and dominating region. The region has a high prevalence of diabetes and a well-established healthcare infrastructure. The presence of key players and ongoing technological advancements in the healthcare sector are also driving market growth in North America.

Key players operating in the Glycated Albumin Assay market include Asahi Kasei Pharma Corporation, Weldon Biotech Inc., Abbexa Ltd., Laboratory Corporation of America, Biocompare, EFK Diagnostics, Elabscience Biotechnology Inc., Abbott, Diazyme Laboratories Inc., Abnova Corporation, BSBE, Maccura Biotechnology Co., Ltd., LifeSpan BioSciences Inc., Biomatik, Geno Technology Inc., AMS Biotechnology (Europe) Limited, Epinex Diagnostics Inc., and DxGen Corp. These key players are actively involved in product development, collaborations, mergers, and acquisitions to strengthen their market position and expand their product portfolio.

Read More:

https://www.pressreleasebulletin.com/glycated-albumin-assay-market-size-and-share-analysis/